--- a
+++ b/clusters/3009knumclusters/clust_155.txt
@@ -0,0 +1,718 @@
+The patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Part B: Patients must have either measurable disease or must be evaluable for MIBG response without evidence of Response Evaluation Criteria in Solid Tumors (RECIST) measurable lesions; patients with neuroblastoma in bone marrow only are not eligible
+Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1).
+Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
+No metastatic disease on cross-sectional imaging (according to Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1 criteria)
+Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Documented radiological evidence for disease progression (measurable or nonmeasurable) =< 12 months prior to enrollment\r\n* NOTE: If patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST)
+Patients must have newly diagnosed, stage IIA – IV disease and must be entered within eight weeks from surgery; they may have either measurable residual disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria, or they may have no measurable residual disease; OR, they must have biopsy-proven recurrent disease of any stage and have never received cytotoxic chemotherapy
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+For patients with solid tumors, one of the following must apply: a. Patient has measurable disease as defined by the immune-related response criteria (irRC), b. Patient has ovarian cancer and has disease evaluable by CA-125 only
+Histologically confirmed solid tumor malignancy that is metastatic or unresectable and have progressed on at least 1 prior therapy and for whom standard curative or palliative measures do not exist or are associated with minimal subject survival benefit. Evaluable or measurable disease, defined as by Response Evaluation Criteria in Solid Tumors (RECIST).
+Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be allowed
+At least one measurable disease site (as defined by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) that has not been previously irradiated
+Measurable or evaluable disease using Response Evaluation Criteria in Solid Tumors
+Patients must have radiographically measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
+Disease must be measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; disease that has undergone local therapy in the past 30 days is not considered measurable unless the investigator has documented progression despite the local therapy (for treatment phase)
+Metastatic or unresectable disease and at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteria; NOTE: Nephrectomy or ablation of the primary tumor is allowed prior to enrollment
+Measurable disease as defined by the tumor specific relevant response criteria for the breast and other solid tumor cohorts (measurable disease is not required for enrollment in the prostate cancer cohort):\r\n* RECIST version 1.1 criteria\r\n* Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria\r\n* RANO criteria
+Women with metastatic breast cancer, measurable or evaluable disease including bone metastasis only (as per the Response Evaluation Criteria in Solid Tumors [RECIST] v1.1)
+Measurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1);
+Dose expansion phase only: must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Measurable by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 (those undergoing pre-treatment resection must have imaging assessment after resection to determine measurability)\r\n* Previously irradiated sites of tumor may be considered measurable if there is radiographic progression at that site subsequent to the time of completing radiation
+Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria
+Presence of measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
+Have measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1
+Measureable disease per response evaluation criteria (RECIST) v1.1
+At least 1 measurable target lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST)
+For all dose expansion arms, participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
+Patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 =< 28 days prior to registration
+Participants enrolled in the Phase I portion must have evaluable disease; participants enrolled in the Phase II portion must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have evidence of radiographic disease progression within the past 12 months; progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria is not required
+Has measureable disease by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) 1.1 criteria.
+Dose expansion only: Subjects must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria; this lesion must be outside a previously irradiated area
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+For Part 1: Participant must have evaluable disease. For Part 2: Participant must have measurable disease according to Response Criteria in Solid Tumors (RECIST) v1.1
+Presence of measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
+Evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
+Must have at least one measurable lesion per irRECIST (immune-related Response Evaluation Criteria Criteria in Solid Tumors):
+Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Palpable lesions that are not measurable by radiologic or photographic evaluations may not be utilized as the only measurable lesion.
+Patients must have at least one “target lesion” to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1; tumors within a previously irradiated field will be designated as “non-target” lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
+Has at least one measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI), according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
+Must have measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) at baseline
+Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease (i.e., present with at least one measurable lesion per Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1)
+Evaluable disease, either measurable on physical examination or imaging by Response Evaluation Criteria in Solid Tumors (RECIST v1.1, Appendix 2), or by informative tumor marker(s).
+Measurable or evaluable disease defined by Response Evaluation Criteria for Solid Tumors (RECIST) ver. 1.1
+For Parts A, B, C, D, E, and F: Have either measureable disease or nonmeasureable but evaluable bone disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
+Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator
+Measurable disease, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Participant must have at least one biopsiable lesion in the Phase 1 portion. In the Phase 2 part of the trial, participants must have either (a) at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or (b) at least one predominantly lytic bone lesion.
+At least 1 measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) meeting the following criteria:
+Measurable unresectable stage III or IV malignant melanoma and Response Criteria in Solid Tumors (RECIST), version 1.1
+Measurable disease per response evaluation criteria in solid tumors.
+Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
+Must have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
+At least one target lesion based on the evaluation criteria in solid tumors (RECIST 1.1).
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Has ?1 distant and/or discrete non-injected lesion that is amenable to biopsy via visual inspection or amenable to biopsy via image guidance, such as ultrasound or computed tomography/magnetic resonance imaging (CT/MRI). This lesion must be measurable as defined by the response criteria used to assess the participant (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] for solid tumors or revised International Working Group [IWG] criteria for lymphomas).
+Presence of measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Presence of measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 is acceptable, except to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable disease by RECIST 1.1 is required
+Assessable disease status defined by Cheson (for lymphoma) or modified severity weighted assessment tool (mSWAT) (for mycosis fungoides [MF] and Sezary syndrome [SS]) criteria, or having measurable tumors defined by Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1) (for solid tumor)
+Have measurable or non-measurable disease per RECIST 1.1 criteria for solid tumors and RANO criteria for HGG
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+The patient must have radiographic measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Phase I: Patients with advanced/metastatic solid tumors, with measurable or unmeasurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST version [v]1.1); baseline measurements must be obtained within 4 weeks prior to registration
+For Part 2 Only: Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, or Triple Negative Breast Cancer with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in at least 1 lesion, that in the opinion of the Investigator is appropriate to treat with nab-paclitaxel.
+At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; a previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the irradiation
+Part A (all cohorts): Have the presence of measureable and /or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
+Have evidence of measurable disease (according to Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1)
+Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
+The patient must have disease that is measurable by standard imaging techniques, per the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), or evaluable per RECIST 1.1. (For patients with prior radiation therapy, measurable lesions must be outside of any prior radiation field[s], unless disease progression has been documented at that disease site subsequent to radiation.)
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
+Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and Immune related Response Criteria (irRC).
+Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in dose escalation; measurable disease by RECIST 1.1 is required in dose expansion
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.
+Measurable disease is required per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
+PHASE I: Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+At least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
+Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria.
+Tumor size is measurable - measurable tumor criteria will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable metastatic melanoma with at least one lesion that is resectable for TIL generation and at least one other lesion that can be measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Patients must have MBC that is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Patients with metastases limited to the bones are eligible.
+Subjects must have measurable disease (Response evaluation criteria in solid tumors (RECIST 1.1))
+Patients must have measurable disease, documented according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, or evaluable disease with a standard tumor marker (alpha-fetoprotein [AFP] and/or human chorionic gonadotropin [HCG]) greater than 10 times the upper limit of normal
+Measurable disease is required according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+PART I: Patients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
+Measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1), modified RECIST or Revised Response Criteria for Malignant Lymphoma
+Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; for example, this would include tumor in the lung, liver, and retroperitoneum; bone disease is difficult to follow and quantify and as a sole site would not be acceptable
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) and obtained by imaging within 30 days prior to being registered for protocol therapy
+Subjects must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
+Participants must have at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 that is amendable to biopsy.
+Subjects must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.
+Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
+Have advanced cancer (metastatic, recurrent or locally advanced) and measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria.
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
+Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
+Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
+The participant has the presence of measurable and/or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria In Solid Tumors (RECIST Version 1.1). Response Assessment in Neuro-Oncology (RANO) Criteria or Macdonald Criteria should be used for CNS tumors.
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
+Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)1.1
+Subjects must have received neoadjuvant chemotherapy (any number of cycles) with complete or partial response as assessed by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST)
+At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria
+Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)1.1 or pure lytic or mixed lytic-blastic bone lesions
+Histologically and/or cytologically confirmed and radiographically measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 colorectal cancer with liver metastasis. Patients may have other sites metastatic disease.
+Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; stage IV or recurrent disease is required
+Presence of at least one lesion with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for response assessment
+Metastatic disease of at least two non-central nervous system (CNS) sites (including the index lesion to be treated) measurable by RECIST criteria with at least one site outside of the radiation field and evaluable by RECIST criteria for evaluation of response
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; patients without measurable disease may be included on study after discussion with the sponsor, given that the primary endpoint of the study is Ki-67 of TIL (flow cytometry)
+Measurable and evaluable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator
+Confirmed diagnosis of one of the following, and must be measurable or evaluable per RECIST 1.1 (solid tumors) or Lugano (NHL):
+Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
+Participants must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
+Patients must have evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+In dose expansion, at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 which can be followed by CT or magnetic resonance imaging (MRI)
+Subjects must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Radiographic tumor assessment performed within 28 days of study inclusion.
+Histological or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and be able to be followed over time by Immune related response criteria (irRC) for treatment decisions
+A minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) \r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)
+Patients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 including at least two metastatic lesions that meet criteria for SBRT radiation\r\n* 0.25 cc to 65 cc of viable tumor (i.e. primary disease or metastases) approximately 5 cm in maximal dimension; tumors larger than 65 cc can be partially treated
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 limited to the abdomen and pelvis
+The subject has a biopsy-proven diagnosis of adenocarcinoma of the pancreas (or recurrence of previously resected disease) with metastatic disease that is measurable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
+Subjects must have measurable disease on physical exam or imaging per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+At least one measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1), local or distant
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Presence of measurable disease by computed tomography (CT) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+At least one measurable tumor lesion as defined by Response Evaluation Criteria in Solid Tumors (Response Evaluation Criteria in Solid Tumors [RECIST]) version (v)1.1 criteria
+Measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1)
+Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
+For dose expansion phase, patients must have at least one site of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1)
+Must have measurable disease by radiographic or physical criteria suitable for evaluation according to RECIST v1.1 for documentation of disease response or progression.
+Have measurable or evaluable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
+Measurable disease (either primary site and/or nodal disease) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 criteria
+Metastatic disease that is evaluable radiologically by Response Evaluation Criteria in Solid Tumors (RECIST) or MD Anderson criteria, which will allow for bone-only disease
+Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
+Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
+Tumor burden must be radiographically measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Patients must have at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.)1.1, determined by investigator review
+Must have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST] 1.1 for those with solid tumors; by Lugano classification for those with NHL), except those with AML, who must have histologically confirmed relapsed or refractory disease.
+Disease must be measurable with at least 1 unidimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.
+At least 2 metastatic sites of which at least 1 must be measurable as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Has measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Documented disease recurrence/progression based on Gynecologic Cancer Intergroup (GCIG)-Response Evaluation Criteria in Solid Tumors (RECIST)
+Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria independent of the lesion irradiated
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have measurable disease with at least 1 unidimensional lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for patients with solid malignancies and evaluable disease as assessed by bone scan and/or positron emission tomography (PET) scan
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for patients with solid malignancies
+Patients must have measurable disease according Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 28 days prior to registration
+Has measurable disease according to Response Criteria for Solid Tumors (RECIST v.1.1)
+For patients enrolled in arm A dose level 4, arm A 14-patients expansion cohort, and arm B (first stage of phase II of TRC102 and pemetrexed) measurable disease is required according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural mesothelioma; pleural effusion and ascites are not considered measurable disease
+Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for patients with solid malignancies
+Progressive disease based on radiological imaging within 12 months; Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 would be used to assess measurable disease burden
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Patients must have measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST) or RECIST; examinations for assessment of measurable disease must have been completed within 28 days prior to registration
+Participants must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the dose escalation portion of the trial. Participants in the expansion cohort must have measurable disease per RECIST version 1.1 or disease evaluable by assessment of tumor antigens.
+At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria that has not been previously irradiated and which can be followed by computed tomography (CT) or magnetic resonance imaging (MRI)
+Patients must have measurable/evaluable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria
+Subjects must have measurable disease on physical exam or imaging per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Have measurable or unmeasurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1; baseline measurements and evaluations must be obtained within < 4 weeks of enrollment; disease in previously irradiated sites is considered measurable if there has been unequivocal disease progression or biopsy-proven residual carcinoma following radiation therapy
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; however, note that patients in Cohort 1 that have undergone an R0 resection will be eligible for the trial
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Measurable or evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+All patients must have measurable lesions according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 must have at least 1 tumour lesion amenable to biopsy, and must be medically fit and willing to undergo a biopsy before first treatment and, unless clinically contraindicated, after 6 weeks on therapy
+Patients with metastasis outside of the abdominal cavity; except\r\n* Disease outside of the abdomen that is non-measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria will be allowed
+At least one clinically evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+All patients must have evaluable disease as defined as:\r\n* Solid tumors must have a lesion evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1\r\n* Central nervous system tumors will be evaluated by Response Assessment in Neuro-Oncology (RANO) criteria\r\n* Leukemia patients must have > 10% blasts (or blast equivalent) in the bone marrow
+Measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
+At least one measurable disease lesion according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1)
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+At least one site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on computed tomography (CT) scan done within 30 days prior to study start
+Measurable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Have a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) and have at least one measurable lesion as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; the target lesion(s) should also have bi-dimensional measurability for RECIST 1.1 evaluation on study
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Version 1.1, 2009);
+Subjects, including those in the dose-escalation portion of the study, must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; imagining must be within 28 days of trial enrollment\r\n* Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site prior to trial enrollment
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Subjects with measurable disease, progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST); the measurable lesion(s) must be outside the field of radiation therapy (RT) if there was prior treatment with RT unless progression at the site has occurred
+Have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
+A minimum of one measurable lesion defined as:\r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)\r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)
+PHASE II SCLC: Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors, version (RECIST 1.1)
+Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); NOTE: Enrollment of patients with bone-only disease may be limited if we find we are not able to get adequate tissue for research correlates from bone biopsies
+Have measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
+Have measurable or evaluable disease based on modified Response Evaluation Criteria in Solid Tumors (RECIST) for mesothelioma
+Presence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable or evaluable indicator lesion(s) as defined by RECIST v1.1; patients without RECIST measurable disease will be eligible for enrollment to \Other\ cohort provided their disease can be evaluated using another accepted response criteria (e.g. Gynecologic Cancer InterGroup [GCIG] CA125 response criteria, positron emission tomography [PET] Response Criteria in Solid Tumors [PERCIST])
+Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
+Measurable disease as defined by immune related Response Criterion (irRC) or Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+At least two measurable lesions (including the index lesion) according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version (v)1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients may have measurable disease only, non-measurable disease only, or both (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
+The patient must have radiographic measurable disease per Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST 1.1) criterion
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Patient must have measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+CAPMATINIB INCLUSION CRITERIA: Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 on screening computed tomography (CT) or magnetic resonance imaging (MRI)
+Patient has measurable disease by RECIST version 1.1 (solid tumors) or Lugano (lymphoma) criteria or evaluable or measureable disease by Macdonald criteria (rHGG).
+Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors Version (RECIST)1.1
+Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+At least one Response Evaluation Criteria in Solid Tumors (RECIST)-defined target lesion; patient must have documented disease progression
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable or evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; tumor lesions previously irradiated or subjected to other loco-regional therapy will only be deemed measurable if progression at the treated site after completion of therapy is clearly documented
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 28 days prior to registration
+Evaluable or measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, and meet the requirements for the intended study cohort
+Has measurable disease based on either RECIST 1.1 for solid tumors or RANO for CNS tumors
+Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
+Presence of measurable recurrence, with Response Evaluation Criteria in Solid Tumors (RECIST) measurable disease at the time of intervention consent
+Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; subjects with evaluable, but not measurable disease will be eligible for phase I
+Patients with any type of malignancies; and/or HIV/AIDs; and/or history of solid organ transplant; and/or Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Measurable or evaluable disease; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, with radiologic scans within 28 days of day 1, cycle 1; evaluable disease must include bone metastases (pleural effusions and ascites are not considered evaluable for this study)
+Patients must have evaluable disease – defined as one of the following:\r\n* Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease OR\r\n* Evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related) AND a cancer antigen 125 (CA125) that has doubled from the post-treatment nadir and is also greater than 2 times upper limit of normal (ULN)
+Have measurable disease based on immune related response criteria (irRC) criteria
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)
+Has clinical response or stable disease for minimum of two months (three cycles of every three week chemotherapy or 8 weeks of weekly regimen, etc.) after receiving any prior chemotherapy for metastatic/recurrent disease; a minimum of two cycles (6-8 weeks) of chemotherapy is required to determine clinical response; per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, clinical response for measurable disease is defined as complete response (CR) or partial response (PR); for non-measurable disease only (i.e. bone metastasis, ascites, pleural effusion, and pathological lymph nodes >= 10 to < 15 mm short axis) is defined as persistence of one or more non-target lesion(s) and no increase in overall tumor burden
+Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Disease progression based on RECIST (Response Evaluation Criteria in Solid Tumors) criteria while the subject has been taking fulvestrant, and for which continuation of endocrine therapy would be appropriate
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
+Histological diagnosis of ameloblastoma; all stages are eligible; patients must have evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients with advanced, measurable metastatic EGA, by Response Evaluation Criteria In Solid Tumors (RECIST) criteria
+Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) (version [v]1.1)
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Progressive disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator within the 12 months preceding study enrollment
+Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
+Have at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumors (RECIST version [v]1.1)
+At least one measurable lesion as assessed by computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Patients must have measurable disease, defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Arms 1E, 2E, 3E: patients with at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 that have not been previously irradiated
+Patients must have one target lesion to be utilized in order to assess response per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+At least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors)
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Patients must have measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version (v)1.1\r\n* Lesions that have previously been treated with stereotactic radiosurgery (SRS) are excluded as measurable disease because distinction of radiation necrosis and tumor progression can be difficult in this setting and enlargement of the lesion may not necessarily mean progression
+Presence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors 1.1
+Patients must have at least one site of measurable disease (if applicable) (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 for solid tumors or the appropriate disease classification/criteria for the target population)
+The target lesion(s) can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST)
+Measurable or evaluable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria
+Patients are not required to have measurable disease by traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria, as lesions in the pancreas are notoriously hard to measure radiographically; however, patients must have disease which is evaluable for resection
+Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; at least one measurable lesion needs to be outside the field of prior therapeutic radiation or has progressed after radiation
+Patients may have either measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+At least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors), or other disease specific response assessment criteria, as appropriate (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
+Measurable tumor according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with at least one unidimensionally measurable target lesion
+Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or physical exam
+A minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
+Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Histologically proven pancreatic adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on imaging as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (or for thymic carcinoma, at least one measurable lesion per International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 criteria
+Measurable or non-measurable (but evaluable) disease as defined via Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
+The target lesion(s) can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST) and must have a maximum tumor volume of =< 100 cm^3
+Stage II of the trial: evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria must be present for all subjects in the randomized component of the trial– if surgery or radiation is planned, the target lesions may not be so treated until after the assessment of the effect of chemotherapy
+Patients with progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria by imaging techniques are not eligible to proceed to the second transplant; tumor marker increase alone is not sufficient to diagnose disease progression
+Documented progression of disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as any progression that requires a change in treatment, prior to randomization
+Measurable disease, that is, presenting with at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
+Participants must have measurable disease as defined by response evaluation criteria in solid tumors (RECIST) 1.1 (soft tissue lesion of greater than or equal to (>=) 10 millimeter (mm) in the long axis or extrapelvic lymph node of >=15 mm in the short axis)
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the site study team. Target tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions;
+At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) in contrast enhanced (unless contraindicated) CT or MRI
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, bone only metastatic disease may be allowed on approval from study principal investigator (PI)
+Subject has measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; tumor lesions situated in previously irradiated areas are considered measurable if progression has been demonstrated in such lesions
+Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
+Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Additional Inclusion Criteria for Dose Finding Part and Dose Expansion Part:
+At least one evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1criteria; (patients whose only nodal disease is cystic and not positron emission tomography [PET]-avid are not eligible)
+Subjects who have measurable disease according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST version 1.1).
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.
+At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in contrast enhanced (unless contraindicated) CT or MRI.
+Patients must have histologically or cytologically confirmed stage IIIB or IV NSCLC with radiographic proof of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Evaluable disease for dose escalation, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for dose expansions
+At least two sites of disease that are measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+RENAL COHORT: Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria in at least one site that is not the site for planned surgical resection or serial biopsy
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator
+Phase II only: Must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Metastatic disease in at least two distinct lesions (including the index lesion to be treated) with at least one site outside of the radiation field and evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for evaluation of response
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for solid tumors
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or at least one site of disease must be uni-dimensionally measurable as per RECIST 1.1. All radiology studies must be performed within 28 days prior to registration
+Histologically proven metastatic pancreatic or colorectal adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for solid tumors, within 28 days prior to registration
+Radiographically measurable disease present per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Bi-dimensionally measurable disease by radiographic imaging (computed tomography [CT] scan) that represents at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and obtained by imaging within 28 days prior to registration for protocol therapy; disease in an irradiated field as the only site of measurable disease is acceptable only if there has been clear progression since completion of radiation treatment
+At least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Patients must have a clinically measurable primary oropharyngeal tumor, defined as measuring >= 1 cm by spiral computed tomography (CT), per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, and/or by clinical examination
+At least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Participant must have measurable disease, as defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 per the Central Radiographic Assessment Committee (CRAC).
+Patients must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST).
+Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1 and >= 1 site safe for biopsy
+Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
+Subjects who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 or elevated tumor markers (human chorionic gonadotropin [hCG], alpha-fetoprotein [AFP])\r\n* Note: patients without measurable disease are allowed on the study as long as they have clearly rising tumor markers and they will be exempt from biopsy
+Patients must have measurable recurrence or metastases, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+ARM A: Histologically or cytologically confirmed hepatocellular carcinoma that is refractory (by Response Evaluation Criteria in Solid Tumors [RECIST] or modified [m]RECIST criteria or with unequivocal clinical progression of disease) to or intolerant (defined as inability to administer further sorafenib due to drug related toxicities) of sorafenib based therapy or advanced solid tumor with liver predominant disease burden that has progressed on or is intolerant to standard
+Measurable disease per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for mesothelioma
+Subjects with extracranial disease must have evaluable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); subjects affected by glioma must have evaluable disease by Response Assessment in Neuro-Oncology Criteria (RANO) criteria
+At least one measureable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Presence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (not required for Part 1); presence of evaluable OR measurable disease for Part 1
+Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+CA-125 only disease without Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable or otherwise evaluable disease
+Have 2 or more measurable sites of disease as defined by either Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or cutaneous lesions at least 1 cm in greatest dimension
+Patients with confirmed diagnosis of ECD that are asymptomatic and with no visceral involvement are not eligible for this trial (patients with no target lesions as per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria)
+Measurable disease per disease specific Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1-patients with bone as their only site of disease will not be eligible
+Must have a minimum of 3 radiographically distinct (> 1.5 cm) lesions measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at time of study enrollment (> 5 preferred)\r\n* A maximum of 2 metastases per treated organ may be targeted for HD-XRT, but must be separated by more than 5 cm of normal tissue\r\n* At least 2 non-irradiated lesions are required for systemic response assessments
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or evaluable cancer via cancer antigen (CA)125 Gynecologic Cancer Intergroup (GCIG) criteria
+Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease, i.e., at least one measurable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria only for expansion cohorts
+Patients enrolled in the dose expansion phase must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumors or measurable nodal disease at baseline as defined by Cheson criteria for lymphoma
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Histologically confirmed, measurable or evaluable disease; patients should have at least one measurable lesion; if applicable, Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be used
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
+Measurable or evaluable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for non-GBM tumors and by Response Assessment in Neuro-Oncology (RANO) criteria for GBM
+Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1
+Evaluable disease, as follows:\r\n* For phase IA dose escalation: have the presence of any evaluable disease, including bone metastases, effusion, or cystic metastases\r\n* For phase IB extension only: have progressive and measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v 1.1)
+All sites of disease must be evaluated within 4 weeks prior to randomization; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have measurable or non-measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to registration (Phase I)
+All patients must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Patients must have at least one site of measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria)
+Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) or non-measurable disease, with measurement obtained within 4 weeks of registration
+Non-measurable and/or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, or abnormal cancer antigen (CA)-125 to levels (in patients with ovarian cancer) at least 1.5 x normal documented by two independent measurements at least 4 weeks apart
+Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria; X-rays, scans or physical examinations used for tumor measurement must have been completed within 28 days prior to registration; X-rays, scans or other tests for assessment of non-measurable disease must have been performed within 42 days prior to registration
+Patients with recurrence must have at least one “target lesion” to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1); tumors within a previously irradiated field will be designated as “non-target” lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
+At least one site of measurable disease as determined by the Investigator, using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+The disease is evaluable by imaging per Response Evaluation Criteria in Solid Tumors 1.1.
+Participants in the randomized portion of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria.
+Has at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as confirmed by the blinded central imaging vendor.
+At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for response assessment (certain exceptions may apply)
+Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Lugano Classification for subjects with DLBCL.
+Measurable or non-measurable (but radiologically evaluable) disease per Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 on computed tomography (CT) scan (within 28 days of randomization) with at least one lesion outside previously irradiated areas.
+Have measurable or non-measurable, evaluable disease by the revised response evaluation criteria in solid tumors (RECIST) v.1.1
+Measurable disease that is evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
+Patients in the phase II portion must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; previously irradiated sites can be included if there is documented progression of disease in that site; patients in the phase I portion do not require measurable disease by RECIST 1.1 criteria
+Patients who have measurable disease must have at least one “target lesion” to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; tumors within a previously irradiated field will be designated as “non-target” lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
+Patients must have disease that can be evaluated radiographically, this may be measurable disease or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+measurable and/or non-measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Disease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
+For the dose-escalation phase, measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 (v1.1) is permitted; for the dose expansion phase, patients must have measurable disease by RECIST v1.1
+Have measurable disease or nonmeasurable but evaluable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or other tumor-specific criteria or disease assessable by physical exam or other methods if not measurable by RECIST
+Measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) criteria
+At least one target lesion that is measurable by RECIST 1.1 for solid tumors, or IWG 2014 for lymphoma
+At least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
+Patients must have measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 9.3 criteria
+Participants must have measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Has at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Subjects who have evaluable lesion per guideline of Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
+Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
+Dose Expansion Phase: at least one measureable lesion as defined by RECIST [Response Evaluation Criterion in Solid Tumors] version 1.1.
+Measurable disease using clinically appropriate criteria for the type of malignancy, RECIST version 1.1 for solid tumors and Cheson 2007 for lymphoma
+Evidence of measurable disease at screening as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
+Participant must have at least 1 unidimensional measurable NSCLC lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1).
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Measurable or non-measurable disease (but radiologically evaluable) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
+Both measurable as well as non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 will be allowed
+As defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the Revised Response Criteria for Malignant Lymphoma or the Response Assessment in Neuro Oncology (RANO) criteria for glioblastoma:
+Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria (for solid tumors) or equivalent criteria (for patients with non-solid tumor malignancies)
+Measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) criteria Version 1.1.
+Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Must have measurable tumor per Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST for malignant pleural mesothelioma
+Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens including but not limited to cancer antigen (CA-125) and prostate-specific antigen (PSA).
+At least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
+At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
+Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST).
+Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as confirmed by the blinded central imaging vendor
+Has measurable disease at baseline based on Response Evaluation Criteria is Solid Tumors (RECIST) 1.1 as determined by the central imaging vendor
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1
+Have evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria within 3 months prior to study enrollment; if the patient was receiving a prior line of systemic therapy, he/she should have evidence of disease progression on that line of treatment prior to enrollment
+Measurable disease as defined by Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST).
+Measureable tumor by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1
+Have measurable disease at the time of study enrollment as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).
+Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only disease
+Patients must have measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST) or RECIST; examinations for assessment of measurable disease must have been completed within 28 days prior to registration
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) (Response Evaluation Criteria in Solid Tumors [RECIST] criteria 1.1)
+Have measureable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
+All sites of disease must be evaluated within 4 weeks prior to beginning therapy; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)
+Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 or bone-only non measurable disease.
+Have either measureable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
+Measurable disease by response evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1) prior to the administration of study treatment
+A minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)\r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)
+Measurable or evaluable disease will be included as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Expansion Phase only: Has measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Version 1.1, 2009), ie, has at least one measurable lesion
+Measurable disease according to modified RECIST (Response Evaluation Criteria In Solid Tumours) criteria
+Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only disease
+Subject has measurable or nonmeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
+A minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)\r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)
+At least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
+The patient must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and must have one site amenable to biopsy that, in the opinion of the investigator and/or interventional radiologist, is likely to yield acceptable tumor sample for a core biopsy per the above pathology criteria
+Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST)
+Patients must have disease (measurable or non-measurable acceptable) according to Response Evaluation Criteria In Solid Tumors (RECIST) v.1.1 criteria
+Disease must be measurable with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
+Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+All sites of disease must be evaluated within 4 weeks prior to beginning therapy; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria or any other baseline prerequisite for the assessment of the principal judgement criteria
+Have a diagnosis of NSCLC with at least 1 measurable lesion assessable using standard techniques by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
+Have the presence of measureable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Subjects with solid tumors, with the exception of castration-resistant prostate cancer (CRPC), must demonstrate measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measureable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
+Participant has radiographically-documented measurable disease, as per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1).
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Presence of measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1, Eisenhauer et al. 2009).
+Measurable disease at the time of study entry as defined by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1).
+Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Target or non-target lesions according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1
+The participant has metastatic disease or locally advanced disease that is measurable or nonmeasurable, but is evaluable disease by radiological imaging per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
+Evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for peritoneal mesothelioma, and modified RECIST for pleural mesothelioma
+Subject has radiological documented measurable disease (ie, at least one measureable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1).
+Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Part 2 only: Measureable tumor (Response Evaluation Criteria In Solid Tumors [RECIST] 1.1)
+Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have measurable disease according to the standard Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, computed tomography (CT) scans or magnetic resonance imagings (MRIs) used to assess the measurable disease must have been completed within 28 days prior to study drug initiation
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1
+Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients should have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; if no measurable disease is present, patients should have assessable disease such as pleural effusion, ascites, with cancer antigen 125 (CA125) Gynecological Cancer Intergroup (GCIG) criteria
+Measurable disease per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; a lesion in a previously irradiated area is ineligible to be considered as measurable disease unless there is objective evidence of progression of the lesion prior to study enrollment
+At least one measureable lesion as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
+Subject must have at least 1 unidimensional measurable NSCLC lesion on a Computerized Tomography (CT) scan as defined by Response Evaluation Criteria In Solid Tumors (RECIST - version 1.1).
+Measurable disease by Computed tomography (CT) or Magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria
+Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumors
+At least one \target lesion\ to be used to assess response, as defined by RECIST 1.1 criteria;
+Measurable or evaluable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1 (v 1)
+Have measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST, v1.1)
+Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors version (RECIST) 1.1 criteria
+Measurable tumor (by Response Evaluation Criteria in Solid Tumors [RECIST] criteria)
+Must have measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease by computed tomography (CT) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 to evaluate response
+Measurable (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) indicator lesion not previously irradiated
+Patients must have measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1])
+No disease progression (i.e. stable disease [SD] or better response by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) at the completion of chemotherapy.
+Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, which includes locoregional lesions (not amenable to curative surgery and/or radiation) and distant metastatic lesions
+Measurable or non-measurable disease is permitted as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) for phase 1b; for phase 2, patients must have measurable disease as defined in RECIST v1.1
+At least 1 lesion on a computed tomography (CT) scan that is measurable as defined by Response Evaluation Criteria In Solid Tumors (RECIST), Version 1.1.
+Patients must have at least one tumor lesion that meets the following criteria: the lesion can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumor (RECIST)
+Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable tumor according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with at least one unidimensionally measurable target lesion
+One or more measurable metastatic tumors measurable on CT san per Response Evaluation Criteria in Solid Tumors (RECIST v.1.1 ), excluding the primary lesion.
+Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to randomization and must be acquired by multiphasic CT or contrast magnetic resonance imaging (MRI)
+Progressive disease after androgen deprivation, as defined by Prostate Cancer Working Group 2 and/or Response Evaluation Criteria in Solid Tumors criteria
+Patients must have at least one site of measurable disease (if applicable) (per RECIST for solid tumors or the appropriate disease classification/criteria for the target population)
+Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable or nonmeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
+Progressive NSCLC: Defined as increasing measurable disease, or the appearance of new measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria despite treatment.
+Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+At least one clinically evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Patients with measurable or non-measurable metastatic disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Patients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 guidelines or evaluable disease; bone metastases must be evaluable
+Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+History of previous response to EGFR-TKI, defined as either a PR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, or at least six months without progressive disease as a result of EGFR-TKI therapy
+Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have a primary or metastatic lesion measurable in at least one dimension by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1 within 4 weeks prior to entry of study
+Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable or non-measurable (but radiologically evaluable) disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria 1.1.
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+At least one measurable lesion and/or non-measurable disease evaluable according to Response Evaluation Criteria In Solid Tumors Version 1.1
+Subjects must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease by Response Evaluation Criteria in Solid Tumors- (RECIST) 1.1 criteria; previous irradiated tumor is acceptable if there is at least a 20% increase in the size of the previously irradiated lesion
+Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in the previously irradiated field
+Subjects must have measurable or evaluable disease; disease sites that are evaluable for progression but not measurable per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1 include:\r\n* Bone lesions\r\n* Previously irradiated lesions\r\n* Cutaneous manifestations (non-discrete lesions only)
+At least one measurable lesion according to response evaluation criteria in solid tumours version 1.1
+Must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+In continuous complete or partial remission or stable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) after standard first-line treatment.
+Measurable disease by (Response Evaluation Criteria in Solid Tumors [RECIST 1.1]) or evaluable disease
+Evidence of unidimensionally measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
+As defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or the Revised Response Criteria for Malignant Lymphoma
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Measurable disease according to Response Evaluation Criteria in Solid Tumors [RECIST 1.1];
+Patient on the dose-escalation portion of the trial must have evaluable disease, defined as either measurable (by Response Evaluation Criteria in Solid Tumors [RECIST]) or non-measurable disease (e.g. bone mets, pleural effusion or lymphangitic spread); measureable disease is required for patients in the expanded RP2D cohort
+Measurable or non-measurable (but evaluable) disease as defined via Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Presence of at least one site of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1
+Have the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). A lesion that has been previously treated by local therapy will qualify as a measurable or evaluable lesion if there was demonstrable progression following locoregional therapy
+Patients must have measurable disease as per the revised Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1)
+Patients may be registered on study prior to completing all chemotherapy but only those having a response or stable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria after 3 to 6 cycles of first-line chemotherapy may proceed on study with SBRT/radiation therapy (RT) treatment
+EXPANSION COHORT ONLY: Participants must have measurable disease, defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
+Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 besides the tumor that is expected to be radiated; bony lesions without soft tissue component are not measurable lesions
+Patient has at least one measurable nodal lesion (>= 2 cm) according to Response Evaluation Criteria in Lymphoma (RECIL) criteria
+Measurable (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]) indicator lesion not previously irradiated
+Measurable and/or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and/or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria; bone only disease is allowed
+Has measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 confirmed by CT or MRI scan within 28 days prior to enrollment.
+Patients must have disease that can be evaluated radiographically; this may be measurable disease or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
+Patient must have at least 1 site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on computed tomography (CT) or magnetic resonance imaging (MRI) which will not be irradiated
+At least 1 measurable target lesion according to Response Evaluation in Solid Tumors (RECIST) 1.1
+Measurable (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) indicator lesion not previously irradiated
+Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v) 1.1 mRECIST or elevated AFP
+At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST).
+Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with progressing or new tumors since last antitumor therapy
+All patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
+Part 2/Dose Expansion Only: Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) outside of any prior radiation field.
+Patient must have at least one target lesion to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented or a biopsy is obtained to confirm persistent disease at least 90 days following completion of radiation therapy
+Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1
+Have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
+Have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CRPC participants may be enrolled with objective evidence of disease as per Prostate Cancer Working Group (PCWG2) criteria
+Measurable indicator lesion by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Patients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Subject has at least 1 measureable lesion (not including any lesion that was irradiated) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
+Patients may have no evidence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or have measurable disease; CA-125 and other available markers will be obtained
+Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
+Measurable disease as measured by response evaluation criteria in solid tumors (RECIST) criteria v 1.1.
+Subjects must have at least 1 measurable or evaluable tumor lesion according to RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, version 1.1)
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Evaluable or measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST).
+Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
+Measurable and/or evaluable disease as per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1) [Groups 1, 2 of Part A and Group 3 of Part B] Inclusion Criteria Part A: MAD
+Eligible study subjects must have histologic or cytologic confirmation of advanced, unresectable or metastatic solid tumors, and have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
+Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
+At least one measurable lesion as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Patients must have measureable disease at screening by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. All scans and x-rays used to document measurable disease must be done within 28 days before enrollment (ascites and bone lesions are not considered measureable disease).
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. All scans and x-rays used to document measurable disease must be done within 28 days before enrollment (ascites and bone lesions are not considered measureable disease).
+Patients must have at least one uni-dimensional measurable lesion by CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST)version 1.1. (applicable only in Phase 2)
+At least 1 solid tumor lesion measurable by computer tomography (CT) scan or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Disease progression by PSA criteria (PSA Working Group Consensus Criteria Eligibility) and/or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Participants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria; baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to registration
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)-1.1 criteria; previous irradiated tumor is acceptable if there is at least a 20% increase in the size of the previously irradiated lesion
+Patients must have evaluable disease; measurable disease is not required; however, if measurable disease is present, it is defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1; furthermore, if only evaluable disease is present, a relevant tumor marker (per investigator discretion) must be >= 2 times upper limit of normal (ULN) at baseline, and can be used as a response indicator
+At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
+Measurable disease defined as 1 or more target lesions according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)
+Have at least 1 extracranial metastasis that is amenable to radiation and at least 1 other site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. At least one measurable lesion must be in the lungs.
+Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria
+Measurable disease based on modified Response Evaluation Criteria In Solid Tumors (RECIST)
+Radiologically measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Patients must have at least one \target lesion\ to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST); tumors within a previously irradiated field will be designated as \non-target\ lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
+Patient’s disease must be bi-dimensionally measurable by caliper or radiological method as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) criteria; for subjects with a single lesion, archived tissue must be available for research analysis; multiple superficial melanoma lesions must have an aggregate total diameter of >=10 mm
+Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Have at least 1 measurable lesion outside of the central nervous system (CNS) whose presence is assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
+Measurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable disease.
+Histologically proven pancreatic adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable and/or evaluable disease based on Response Evaluation Criteria in Solid\n             Tumors (RECIST version 1.1)
+Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) For multiple myeloma only:
+Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1
+Patients must have measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1
+Has measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+For escalation: documentation by established staging studies or clinical examination to have measurable or non-measurable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
+Patient must have previously progressed on abiraterone (either by PCWG2 criteria or Response Evaluation Criteria in Solid Tumors [RECIST] criteria)
+Progression in measurable disease Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at the time of study entry
+All patients enrolled will be required to have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria outside the radiation field
+Radiographically documented measurable disease at study entry per response evaluation criteria in solid tumours ( RECIST) v1.1.
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) on imaging studies CT
+Progressive disease as demonstrated by a rising PSA (at least two determinations) prior to study entry, and/or radiographic evidence of tumor progression in soft tissue according to modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria or identification of new lesions by bone scan (i.e., >= 2 new lesions)
+Measurable (Response Evaluation Criteria In Solid Tumors [RECIST 1.1]) indicator lesion not previously irradiated
+At least one measurable lesion according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
+Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Metastatic or advanced breast cancer that is evaluable OR metastatic or advanced breast cancer that is measurable for response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+At least one target lesion that has not been treated with local therapy and is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
+Evaluable disease or disease measurable per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
+Previously treated with trametinib on Arm A and experienced objective disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have achieved a complete response (CR) or partial response (PR), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, following treatment for recurrent ovarian, fallopian tube, or peritoneal cancer; histological confirmation of the original primary tumor is required
+Radiographically evaluable (measurable or non-measurable) disease (according to modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria
+Presence of either evaluable disease or measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have measurable disease as defined by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); baseline measurements must be obtained within 4 weeks prior to initiating therapy; at least 1 of the tumor sites must be amenable to surgical or core biopsy
+Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
+Patients may have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1 or non-measurable tumors
+The subject has measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
+Subjects must have measurable disease (Response evaluation criteria in solid tumors (RECIST 1.1)
+Patients with measurable or non-measurable disease according to the response evaluation criteria in solid tumors (RECIST , v1.1)
+Evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) v.1.1
+Patients with measurable or evaluable disease according to the response evaluation criteria in solid tumors
+Metastatic disease documented on diagnostic imaging studies with measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Measurable disease according to Response Criteria for Solid Tumors (RECIST Version 1.1)
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Soft tissue disease progression as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Radiographically measurable disease; measurable disease is defined as disease that can be assessed with 2-dimensional measurements on a cross-sectional imaging; minimum lesion size is 2 cm in greatest diameter as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
+Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
+Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
+Presence of at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
+Measurable or evaluable disease according to RECIST for solid tumors or according to IWRC for NHL tumors
+Disease that is measurable per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
+Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Subjects with advanced and/or metastatic solid tumors or B-NHL who are either refractory to or have relapsed from standard therapies, or for whom a standard therapy does not exist with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Participants must have measurable disease by response evaluation criteria in solid tumors (RECIST) version (v) 1.1 or bone-only disease with radiologic scans
+Documented progressive disease based on investigator assessment according to Response Evaluation Criteria in Solid Tumours (RECIST) following receipt of at least two cycles of cisplatin or carboplatin administered for R/M disease
+Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients enrolled in the dose expansion phase must have at least one measurable lesion as defined by RECIST criteria for solid tumors or Measurable nodal disease at baseline as defined by Cheson criteria for Lymphoma.
+Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) (for phase II part only)
+The participant has measurable or nonmeasurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 guidelines.
+Patients must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria that has not been previously irradiated; if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation
+Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
+Histologically confirmed, measurable or evaluable disease; if disease is measurable Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be used
+Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1
+Patients must have measurable disease either primary and/or metastatic masses reproducibly measurable in one or two diameters by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 parameters by CT scan or MRI scan; positron emission tomography (PET) or octreotide scans are useful adjuncts but will not be used to measure response
+Patients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Patients must have computed tomography (CT) measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
+Phase Ib: Have evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at the time of study entry
+Documented radiological evidence for disease progression (measurable or nonmeasurable) =< 12 months prior to enrollment; NOTE: if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; at least one measurable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST)
+Cutaneous tumor deposits that, in the opinion of the investigator are amenable to sequential biopsies for correlative analyses; in addition to these, all patients must have measurable disease (i.e., present with at least one measurable lesion per Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1)
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Symptoms uncontrolled by somatostatin analogues OR morphologically progressive tumor by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in the liver OR baseline tumor burden > 25% of the liver volume
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
+Participants must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens:
+Have evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and/or Prostate Cancer Working Group 2 (PCWG2) criteria
+Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria
+Patients must have measurable or evaluable/non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; patients with bone only disease are not eligible; NOTE: for patients with metastatic disease in the liver, tumor burden should not be deemed significant (e.g., to no more than 30% of total liver volume as assessed by local review/investigator)
+?1 measurable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 that has not been previously treated with locoregional therapy. A participant with a lesion(s) that has previously been treated with locoregional therapy is also eligible, if the lesion has documented progression after locoregional treatment and is measureable.
+Patients must have either measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) or evaluable disease (non-measurable lesions) outside irradiated field on computed tomography (CT)/magnetic resonance imaging (MRI)
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
+Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1, see Section 9)
+Disease may be measurable (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) or non-measurable but must be present in at least one non-liver site, where presence is defined as 1.5 cm or greater and visualized on PET/CT with [18F]-fluorodeoxyglucose (FDG); patients with effusion only disease or disease only in the liver are not eligible for the study
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
+Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
+Have measurable disease based on RECIST version (v) 1.1 for solid tumors
+Disease may be measurable (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) or non-measurable but must be present in at least one non-liver site, 1.5 cm or greater and visualized on PET/CT with [18F]-fluorodeoxyglucose (FDG). Patients with effusion only disease or disease only in the liver are not eligible for the study.
+Must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 regardless of disease stage (e.g. localized, locally advanced, or metastatic)
+Disease measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, a mass of greater than 1 cm in the long axis and/or other tumor response criteria from an MSKCC institutional review board (IRB)-approved clinical research protocol; NOTE: study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment
+Disease measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or other tumor response criteria from an MSKCC Institutional Review Board (IRB)-approved clinical research protocol; NOTE: Study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment
+Patients must have measureable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Eligible adult patients currently meeting inclusion criteria and will be treated with an investigational or recently approved therapeutic agent at HCI; the patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; RECIST imaging must be current and have been obtained within 30 days prior to the baseline imaging session
+Has measureable disease by Response Evaluation Criteria In Solid Tumors (RECIST)
+Subjects must have measurable disease by CT or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; to comply with PET Response Criteria in Solid Tumors (PERCIST) criteria, subjects should have at least one lesion measuring at least 2 cm in the longest diameter
+Presence of at least one measurable lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST)
+Subjects are required to have measurable disease that has progressed through prior therapy and that includes a non-hepatic lesion for imaging that is >= 1.5 cm, as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST)
+Subjects must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
+At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
+Has measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria at presentation
+Measurable disease according to RECIST v.1.1 (or Choi criteria and/or EORTC metabolic response criteria for solid tumors, in the case of GIST); or
+Additional Inclusion Requirements for expansion cohorts only a) Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (Version 1.1) and at least 1 nonsignificant risk, non-target lesion accessible for biopsy per the guidelines above (for TAK-580 + nivolumab and TAK-202 (plozalizumab) + nivolumab only).
+Measurable disease according to Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST)
+Has measurable disease based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by local radiology review.
+Have presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
+Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
+Recurrent or metastatic disease, documented by imaging (CT scan, MRI, X-ray) and/or physical examination. In phase II, measurable disease as per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 is mandated. In phase Ib, patients with or without measurable disease are eligible.
+Subject must have evaluable, progressive, and measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, Version 1.1